GlassScriptPhysician profile
Melvin B Saltzman
NPI 1124025416
$2,912.30
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $276 · 2021: $679 · 2022: $1,391 · 2023: $174 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.35 | 2019-2023 | Vraylar, Skyrizi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $506.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.86 | 2021-2022 | |
| Janssen Biotech, INC. | $272.26 | 2021-2022 | |
| Novo Nordisk INC | $208.96 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $135.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.15 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $125.27 | 2024 | Voquezna |
| Amgen INC. | $117.07 | 2020-2023 | Avsola |
| Braintree Laboratories, INC. | $107.01 | 2021-2022 | |
| Gilead Sciences, INC. | $54.25 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $30.29 | 2022 | |
| Shionogi INC | $22.86 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.00 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.77 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.81 | 2019 | |
| Intercept Pharmaceuticals, INC. | $15.08 | 2022 | |
| Allergan, INC. | $13.76 | 2019 | |
| Redhill Biopharma INC. | $13.05 | 2022 | |
| Qol Medical, LLC | $9.60 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Saltzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.